Loading...

FITC anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
rb6-8c5
C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
  • rb6-8c5
    C57BL/6 mouse bone marrow stained with Ly-6G/Ly-6C (clone RB6-8C5) FITC and CD11b PE.
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
108405 50 µg $24
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108406 500 µg $127
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  3. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  4. Zhang J, et al. 2015. PLoS One. 10:130441. PubMed
  5. Montagner S, et al. 2016. Cell Rep. 15: 1566-1579. PubMed
  6. D'Alessandro G, et al. 2020. Eur J Immunol. 50:705. PubMed
  7. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  8. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  9. Furuhashi K, et al. 2017. Immunology. 151:227. PubMed
  10. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  11. Gan C, et al. 2022. Respir Res. 23:32. PubMed
  12. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  13. Guan F, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0446-7. PubMed
  14. Kitur K, et al. 2016. Cell Rep. 16:2219-2230. PubMed
  15. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  16. Jackson A, et al. 2014. J Leukoc Biol. 92:609. PubMed
  17. Jones NM, et al. 2019. BMC Cancer. 1.127777778. PubMed
  18. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  19. Chen X, et al. 2021. Theranostics. 11:4655. PubMed
  20. Morimura S, et al. 2013. Am J Pathol. 182:6140. PubMed
  21. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  22. Zhang Z, et al. 2020. J Immunol. 204:3400. PubMed
  23. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
  24. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  25. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  26. Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
  27. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  28. Wang X, et al. 2016. PLoS Pathog. 12: 1005367. PubMed
  29. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  30. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  31. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  32. Herman KD, et al. 2022. Front Immunol. 13:956991. PubMed
  33. Martin R, et al. 2014. J Leukoc Biol. 96:151. PubMed
  34. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  35. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  36. Karachi A, et al. 2019. Neuro Oncol. 1.381944444. PubMed
  37. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  38. Pawaria S, et al. 2020. Arthritis Rheumatol. 72:359. PubMed
  39. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  40. Blijswijk J, et al. 2015. J Immunol. 194:307. PubMed
  41. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  42. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  43. Wang C, et al. 2017. J Immunol. 10.4049/jimmunol.1700671. PubMed
  44. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  45. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  46. Fang R, et al. 2019. Mucosal Immunol. 12:1092. PubMed
  47. Piao W, et al. 2020. Cell Reports. 30(4):1052-1062.e5.. PubMed
  48. Qi X, et al. 2019. Nat Med. 25:1225. PubMed
  49. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  50. Kakizaki M, et al. 2021. Cell Death Dis. 12:1010. PubMed
  51. Suo J, et al. 2014. J Leukoc Biol. 96:133. PubMed
  52. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  53. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  54. Dong S, et al. 2021. Nature. 591:117. PubMed
  55. Jaworska K, et al. 2015. J Immunol. 194:325. PubMed
  56. Shankar J 2016. Innate Immunity. 22: 31 - 39. PubMed
  57. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  58. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  59. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  60. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  61. Morimura S, et al. 2021. Int J Mol Sci. :22. PubMed
  62. Greenwald AC, et al. 2019. J Exp Med. 216:215. PubMed
  63. Codina A, et al. 2019. Cell Syst. 8:136. PubMed
  64. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  65. Wang H, et al. 2022. J Nanobiotechnology. 20:445. PubMed
  66. Shen X, et al. 2021. Front Immunol. 12:710750. PubMed
  67. Kren N, et al. 2020. Sci Rep. 10:7390. PubMed
  68. Bei T, et al. 2021. Molecules. 26:. PubMed
  69. Nguyen GT, et al. 2021. iScience. 24(8):102871. PubMed
  70. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  71. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  72. Siamishi I, et al. 2020. Cell Reports. 31(11):107756. PubMed
  73. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  74. Wara AK, et al. 2020. Cell Rep. 33:108550. PubMed
  75. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  76. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  77. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  78. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  79. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  80. Zhai K, et al. 2021. Nat Cancer. 2:1136. PubMed
  81. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  82. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  83. Uderhardt S, et al. 2019. Cell. 177:541. PubMed
  84. Wang Q, et al. 2018. Int J Biol Sci. 14:147. PubMed
  85. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  86. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  87. Yamada D, et al. 2014. J Immunol. 192:4112. PubMed
  88. Ish-Shalom E, et al. 2016. J Immunol. 196: 156 - 167. PubMed
  89. Xi‐Zhi J Guo et al. 2018. Immunity. 49(3):531-544 . PubMed
  90. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  91. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  92. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  93. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  94. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  95. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  96. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  97. Tuong ZK, et al. 2021. Cell Rep. 37:110132. PubMed
  98. Kitur K, et al. 2015. PLoS Pathog. 11:1004820. PubMed
  99. Chen Z, et al. 2016. PLoS One. 11: 0146681. PubMed
  100. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  101. Chen C, et al. 2020. Cell Rep. 2136:30. PubMed
  102. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  103. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  104. Mesa-Nuñez C, et al. 2022. Mol Ther Methods Clin Dev. 26:459. PubMed
  105. Avalle L, et al. 2020. Mol Ther Methods Clin Dev. 0.793055556. PubMed
  106. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  107. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  108. DiMenna L, et al. 2010. J Immunol. 184:5475. PubMed
  109. Maulhardt HA, et al. 2020. Invest New Drugs. 1618:38. PubMed
  110. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  111. Iwanami N, et al. 2020. iScience. 23:101260. PubMed
  112. Chauhan P, et al. 2014. Int Immunopharmacol. 21:63. PubMed
  113. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  114. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  115. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  116. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  117. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  118. Saul S, et al. 2019. J Leukoc Biol. N/A. PubMed
  119. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  120. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  121. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  122. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  123. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  124. Qu J, et al. 2021. Int J Biol Sci. 17:2756. PubMed
  125. Maicas N, et al. 2017. PLoS One. 12(2):e0168981. PubMed
  126. An J, et al. 2015. Biochem Biophys Res Commun. 461:142. PubMed
  127. Morales J, et al. 2014. J Leukoc Biol. 95:643. PubMed
RRID
AB_313370 (BioLegend Cat. No. 108405)
AB_313371 (BioLegend Cat. No. 108406)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Go To Top Version: 2    Revision Date: 12/09/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account